Explore 3 Stock Ideas & Industry Insights Download Free Report

PetVivo Holdings Inc

Company price
0.6299 USD 0.01 ( 1.78%)
Last update at 2026-11-06T20:45:00Z
VOLUME
8690
Market Cap
26.57M

Momentum Score

…

PetVivo Holdings, Inc., a biomedical device company, manufactures, commercializes, and licenses medical devices and therapeutics for animals in the United States. The company's lead product is Spryng, a veterinarian-administered, intraarticular injection for the management of lameness and other joint afflictions, such as osteoarthritis in dogs and horses. It also provides therapeutic devices for veterinary and human clinical applications. The company is based in Edina, Minnesota.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.61
Low
0.63
High
52 Week Price Range
0.59
Low
1.69
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

PetVivo Holdings Inc is an OTC-traded microcap that states it develops medical products for veterinary and potential human use, but public disclosures are limited. Long-term growth may be driven by successful commercialization, regulatory clearances and licensing or distribution agreements amid rising veterinary healthcare demand.
Key risks include an early-stage, largely unproven product portfolio, limited disclosure and thin trading liquidity, plus regulatory and financing requirements that could prevent commercialization.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.62
Dividend Yield
-
Revenue TTM
1.18M
Revenue Per Share
0.04
Gross Profit TTM
0.79M
Debt / Equity
0.17
ROE
-384.36%
Net Debt
0.18M
ROCE
-427.74%
Diluted EPS TTM
-0.33

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2026-03-31 2025-03-31 2024-03-31 2023-03-31 2022-03-31
Type yearly yearly yearly yearly yearly
Date 2026-03-31 2025-03-31 2024-03-31 2023-03-31 2022-03-31
Income before tax -10.47M -8.40M -10.96M -8.72M -5.01M
Net income -10.47M -8.40M -10.96M -8.70M -4.94M
Selling general administrative 4.33M 4.82M 6.69M 5.02M 3.15M
Selling and marketing expenses 3.07M 2.64M 3.40M 3.41M 1.35M
Gross profit 0.75M 0.99M 0.74M 0.39M -0.09M
Reconciled depreciation 0.54M 0.35M 0.13M 0.11M 0.07M
Ebit -9.41M -8.04M -10.62M -8.85M -5.06M
Ebitda -8.86M -7.69M -10.49M -8.73M -5.02M
Depreciation and amortization 0.54M 0.35M 0.13M 0.11M 0.03M
Operating income -8.06M -8.06M -10.62M -8.73M -5.06M
Other operating expenses 9.20M 9.19M 11.59M 9.65M 5.17M
Interest expense 1.07M 0.36M 0.01M 0.02M 0.04M
Tax provision 0.00M 0.00M 0.00M 0.00M 0.00M
Interest income 0.01M 0.00M - 0.02M -
Net interest income -1.05M -0.36M -0.01M 0.02M 0.01M
Income tax expense - - 0.72M -0.02M -0.07M
Total revenue 1.14M 1.13M 0.97M 0.92M 0.12M
Total operating expenses 8.82M 9.05M 11.36M 9.12M 4.97M
Cost of revenue 0.39M 0.14M 0.23M 0.53M 0.20M
Total other income expense net -2.41M -0.34M -0.33M 0.02M 0.04M
Net income from continuing ops -10.47M -8.40M -10.96M -8.72M -5.01M
Net income applicable to common shares - - - - -5.01M
Breakdown 2026-03-31 2025-03-31 2024-03-31 2023-03-31 2022-03-31
Type yearly yearly yearly yearly yearly
Date 2026-03-31 2025-03-31 2024-03-31 2023-03-31 2022-03-31
Total assets 3.58M 9.34M 3.12M 2.44M 7.43M
Intangible assets 1.20M 1.97M 0.03M 0.04M 0.05M
Other current assets 0.27M 0.45M 0.55M 0.49M 0.55M
Total liab 1.38M 5.12M 2.43M 1.71M 1.44M
Total stockholder equity 2.20M 4.22M 0.69M 0.73M 5.99M
Other current liab 0.33M 1.40M 0.24M 0.79M 0.78M
Common stock 0.04M 0.02M 0.02M 0.01M 0.01M
Capital stock 0.04M 0.03M 0.02M 0.01M 0.01M
Retained earnings -102.08M -91.20M -82.80M -71.84M -63.13M
Other assets - - - - 0.01M
Cash 0.20M 0.23M 0.09M 0.48M 6.11M
Total current liabilities 1.38M 4.32M 1.41M 1.45M 1.17M
Current deferred revenue 0.12M - - -0.01M -
Net debt 0.18M 2.67M 1.28M -0.13M -5.77M
Short term debt 0.38M 2.10M 0.35M 0.09M 0.07M
Short long term debt 0.32M 1.94M 0.16M 0.01M 0.01M
Short long term debt total 0.38M 2.90M 1.37M 0.35M 0.33M
Other stockholder equity 104.23M 95.39M 83.47M 72.56M 69.10M
Property plant equipment - - - - 0.61M
Total current assets 1.86M 5.61M 1.04M 1.42M 6.76M
Net tangible assets - - - - 5.94M
Short term investments 0.15M 0.15M 0.00M - -
Net receivables 0.70M 4.46M 0.02M 0.09M 0.00M
Long term debt - 0.01M 1.00M 0.02M 0.03M
Inventory 0.54M 0.32M 0.39M 0.37M 0.10M
Accounts payable 0.55M 0.82M 0.82M 0.59M 0.32M
Non currrent assets other 0.01M 0.03M 0.03M 0.03M 0.01M
Non current assets total 1.72M 3.73M 2.07M 1.01M 0.67M
Capital lease obligations 0.05M 0.96M 0.20M 0.32M 0.30M
Breakdown 2026-03-31 2025-03-31 2024-03-31 2023-03-31 2022-03-31
Type yearly yearly yearly yearly yearly
Date 2026-03-31 2025-03-31 2024-03-31 2023-03-31 2022-03-31
Investments 0.01M -0.56M -0.31M -0.42M -0.18M
Change to liabilities - - - 0.26M 0.14M
Total cashflows from investing activities 0.01M -0.56M -0.31M -0.42M -0.18M
Net borrowings 0.14M 2.16M 0.81M -0.01M -0.08M
Total cash from financing activities 6.07M 6.03M 7.34M 1.59M 10.44M
Change to operating activities - - - -0.07M -0.24M
Net income -10.47M -8.40M -10.96M -8.72M -5.01M
Change in cash -0.03M 0.14M -0.39M -5.63M 6.08M
Begin period cash flow 0.23M 0.09M 0.48M 6.11M 0.02M
End period cash flow 0.20M 0.23M 0.09M 0.48M 6.11M
Total cash from operating activities -6.11M -5.32M -7.42M -6.79M -4.17M
Issuance of capital stock 5.08M 3.87M 6.53M 1.53M 10.20M
Depreciation 0.54M 0.35M 0.13M 0.11M 0.07M
Other cashflows from investing activities 0.02M -0.50M -0.31M - -
Dividends paid 0.40M - - - -
Change to inventory -0.45M 0.07M -0.02M -0.27M -0.10M
Change to account receivables -0.05M -0.04M 0.07M -0.08M -0.00M
Other cashflows from financing activities 0.40M 1.82M -0.31M 0.07M 0.32M
Change to netincome - - - 1.97M 0.98M
Capital expenditures 0.01M 0.56M 0.31M 0.42M 0.18M
Change in working capital -0.90M 0.28M 0.17M -0.16M -0.20M
Stock based compensation 1.88M 1.48M 2.63M 1.46M 0.70M
Other non cash items 2.84M 0.97M 0.61M 0.51M 0.27M
Free cash flow -6.12M -5.89M -7.73M -7.22M -4.36M

Peer Comparison*

Sector: Healthcare Industry: Medical Devices

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
PETV
PetVivo Holdings Inc
0.01
1.78%
0.63 - - 22.48 19.38 22.49 -8.68
ABT
Abbott Laboratories
-0.03
0.03%
109.93 25.97 17.24 3.57 3.20 3.81 16.75
MDT
Medtronic PLC
-3.04
2.90%
101.80 26.60 15.87 3.35 2.08 3.90 14.12
SYK
Stryker Corporation
-9.21
2.75%
325.87 29.23 16.86 4.18 4.51 4.63 17.16
SEMHF
Siemens Healthineers AG
-2.15
4.12%
49.85 39.57 21.32 3.01 3.29 2.95 16.92

Profile*

PetVivo Holdings Inc

PetVivo Holdings, Inc., a biomedical device company, manufactures, commercializes, and licenses medical devices and therapeutics for animals in the United States. The company's lead product is Spryng, a veterinarian-administered, intraarticular injection for the management of lameness and other joint afflictions, such as osteoarthritis in dogs and horses. It also provides therapeutic devices for veterinary and human clinical applications. The company is based in Edina, Minnesota.

5151 Edina Industrial Boulevard, Edina, MN, United States, 55439

952 405 6216

22

Name Title Year Born
Mr. John Lai CEO, Pres & Director 1962
Mr. Robert J. Folkes Chief Financial Officer 1963
Mr. Randall A. Meyer Chief Operating Officer 1964
Mr. Randy Wenthold Chief Science Officer NA
Mr. John F. Dolan Gen. Counsel, Chief Bus. Devel. Officer & Sec. 1965
Mr. Gary DeMel Exec. VP of Bus. Devel. 1957
Mr. Russell Siakel Director of Marketing NA
Mr. Mark Middleton National Director of Sales NA
Mr. John Lai CEO, President & Director 1962
Mr. Garry N. Lowenthal Chief Financial Officer 1959

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…